PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung Cancer

INTRODUCTION: PRONOUNCE compared the efficacy and safety of pemetrexed+carboplatin followed by pemetrexed (Pem+Cb) with paclitaxel+carboplatin+bevacizumab followed by bevacizumab (Pac+Cb+Bev) in patients with advanced nonsquamous non–small-cell lung cancer (NSCLC). METHODS: Patients ≥18 years of age...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Thorac Oncol
Main Authors: Zinner, Ralph G., Obasaju, Coleman K., Spigel, David R., Weaver, Robert W., Beck, J. Thaddeus, Waterhouse, David M., Modiano, Manuel R., Hrinczenko, Borys, Nikolinakos, Petros G., Liu, Jingyi, Koustenis, Andrew G., Winfree, Katherine B., Melemed, Symantha A., Guba, Susan C., Ortuzar, Waldo I., Desaiah, Durisala, Treat, Joseph A., Govindan, Ramaswamy, Ross, Helen J.
Formato: Artigo
Idioma:Inglês
Publicado em: Lippincott Williams & Wilkins 2015
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4276572/
https://ncbi.nlm.nih.gov/pubmed/25371077
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0000000000000366
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados